Glomerulonephritis Acute
Conditions
Keywords
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Pauci-Immune Vasculitis, Churg-Strauss Syndrome, Granulomatosis with Polyangiitis, Microscopic Polyangiitis, urinary biomarker, outcome, prediction,, urinary effector memory T lymphocytes, glomerulonephritis, non-invasive biomarker, flow cytometry, treatment outcome, CD4-Positive T-Lymphocytes/immunology
Brief summary
Urinary T lymphocytes may be predictive for clinical outcome in patients with ANCA associated glomerulonephritis (ANCA GN). The investigators hypothesize that the amount of CD4+ effector/memory T cells in urine at time of diagnosis predicts the outcome of patients with active ANCA GN after 6 months of therapy. In a prospective, six-months follow-up study patients' urine will be analysed by flow cytometry every 60 days (+/- 10d). Treatment will be performed to the discretion of the treating clinician. After 6 months of treatment response will be determined as either complete response or partial response.
Interventions
Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes. T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326
Sponsors
Study design
Eligibility
Inclusion criteria
* Informed consent * Biopsy proven ANCA related glomerulonephritis * In absence of biopsy clinical diagnosis of ANCA related glomerulonephritis
Exclusion criteria
* Biopsy proven non-ANCA related kidney disease * Active menstrual bleeding * Urinary tract infection * Kidney transplantation during observational period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phenotype of CD4+ T cells at time point 0 predictive of clinical outcome in patients with active ANCA-assosciated glomerulonephritis | 6 months | Urinary CD4+ effector/memory T cell counts at time point 0 (time of diagnosis) predict clinical outcome (complete or partial response) after 6 months of treatment in patients with active ANCA-assosciated glomerulonephritis. The frequency of effector/memory CD4+ T lymphocytes is higher in patients with non- or partial response. Complete response at 24 weeks: BVAS = 0 Partial response at 24 weeks: at least one renal element of the BVAS score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of patients with persistent renal abnormalities as partial response | 6 months | — |
| Phenotype of CD8+ T cells at time point 0 predictive of clinical outcome in patients with active ANCA-assosciated glomerulonephritis | 6 months | Urinary CD8+ effector/memory T cell counts at time point 0 (time of diagnosis) predict clinical outcome (complete or partial response) after 6 months of treatment in patients with active ANCA-assosciated glomerulonephritis. The frequency of effector/memory CD8+ T lymphocytes is higher in patients with non- or partial response. |
| Subgroup analysis according to treatment | 6 months | — |
| Diagnosis of active glomerulonephritis in Patients with ANCA associated vasculitis | 6 months | Diagnosis according to initial T cell count |
| Prediction of complete or partial response according to normalization of the amount of urinary T cells at time point 2 and 4 | 6 months | — |
Countries
Germany, United Kingdom